New market study, "Qatar Pharmaceuticals & Healthcare Report Q3 2016", has been published

Rising demand for healthcare, as well as public and private investment in healthcare infrastructure, will translate to commercial opportunities for pharmaceutical and healthcare operators in Qatar over the forecast period. However, we highlight a deceleration in the pace of government investment in healthcare capital projects as authorities will instead prioritise infrastructure projects related to the FIFA 2022 World Cup. Moreover, Qatar's government will attempt to contain buoyant healthcare costs through the promotion of a greater role by private health insurance providers in the health system, aside from the recent downward price revision for several drug segments in an attempt to harmonise drug prices across the Gulf Cooperation Council bloc .

Full Report Details at
- http://www.fastmr.com/prod/1197546_qatar_pharmaceuticals.aspx?afid=301

Headline Expenditure Projections

Pharmaceuticals: QAR1.91bn (USD524mn) in 2015 to QAR2.03bn (USD557mn) in 2016; +6.4% in local currency and US dollar terms. Forecast broadly in line with last quarter .

Healthcare: QAR17.55bn (USD4.82bn) in 2015 to QAR18.54bn (USD5.09bn) in 2016; +5.7% in both local currency and US dollar terms. Forecast revised downwards from last quarter .

Risk/Reward Index

In Q316, we have revised downwards Qatar's Risk/Reward Index score to 52.4 from 53.6 in the last quarter (out of 100). Qatar's score was revised mainly due to lower sector value growth indices. Qatar shifted down one ranking position to sixth out of 31 countries monitored in the Middle East and Africa region in terms of market attractiveness to pharmaceutical investors. Qatar's score is driven by high spending per capita on medicine and high sector value growth, but is dragged down by a small market size and a small pensionable population.

Latest Updates

In June 2016, Qatar's Ministry of Public Health (MOPH) announced that the launch of the new health insurance scheme - which is aimed at increasing the role of private insurers in the health system - will be postponed from mid-2016 to 2017.

In May 2016, Qatar's Public Works Authority (Ashghal) announced that it would award contracts for the construction of only three healthcare centres in Qatar, compared to the seven that had previously been planned for the current year. As such, Ashghal will spend around QAR2.5bn (USD687mn) on the construction of new primary health facilities in 2016, down from the previously planned allocation of QAR7.0bn (USD1.9bn).

In April 2016, the prices of 400 medicines were reduced by an average of over 26% in the third and latest phase of the price cut plan carried out over the last two years in Qatar, a trend that will continue to draw more customers to private pharmacies.

BMI Economic View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Turkey Pharmaceuticals & Healthcare Report Q3 2016
- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- United Arab Emirates Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016